GENSCRIPT BIOTECH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.44 HKD | -8.90% |
|
-17.80% | -47.43% |
| Sales 2023 | 840M 6.58B | Sales 2024 * | 1.27B 9.98B | Capitalization | 2.83B 22.17B |
|---|---|---|---|---|---|
| Net income 2023 | -95M -744M | Net income 2024 * | -111M -869M | EV / Sales 2023 | 6.43 x |
| Net cash position 2023 * | 671M 5.26B | Net cash position 2024 * | 606M 4.74B | EV / Sales 2024 * | 1.75 x |
| P/E ratio 2023 |
-56.1
x | P/E ratio 2024 * |
-27.9
x | Employees | 6,937 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 54.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genscript Biotech Corporation
More press releases
| 1 day | -8.90% | ||
| 1 week | -17.80% | ||
| Current month | -28.00% | ||
| 1 month | -37.63% | ||
| 3 months | -39.72% | ||
| 6 months | -47.17% | ||
| Current year | -47.43% |
1 week
10.34
12.82
1 month
10.3416.04
Current year
10.3419.84
1 year
10.3424.95
3 years
10.3443.40
5 years
9.6643.40
10 years
1.0743.40
| Managers | Title | Age | Since |
|---|---|---|---|
Weihui Shao
CEO | Chief Executive Officer | - | 22-12-31 |
Ye Wang
FOU | Founder | 55 | 01-12-31 |
Shiniu Wei
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Xin Guo
BRD | Director/Board Member | 61 | 15-08-23 |
Li Zhu
BRD | Director/Board Member | 74 | 09-12-31 |
Xue Hai Wang
BRD | Director/Board Member | 50 | 20-11-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.61% | 4 M€ | -27.92% | ||
| 1.43% | 2 M€ | -20.87% | - | |
| 0.56% | 3 M€ | -6.96% | - | |
| 0.49% | 2 M€ | -.--% | ||
| 0.47% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 10.44 | -8.90% | 30 405 976 |
| 24-04-18 | 11.46 | -0.35% | 5,936,047 |
| 24-04-17 | 11.5 | -1.20% | 13,562,450 |
| 24-04-16 | 11.64 | -4.28% | 15,156,400 |
| 24-04-15 | 12.16 | -4.70% | 15,713,380 |
Delayed Quote Hong Kong S.E., April 19, 2024 at 04:08 am EDT
More quotes
Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
1.333
USD
Average target price
3.688
USD
Spread / Average Target
+176.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -47.43% | 3.11B | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- 1548 Stock
